SAUDI-SPORTS-FOR-ALL
11.2.2024 22:19:26 CET | Business Wire | Press release
More than 20,000 participants from 125 countries, including a record 60% Saudi nationals, took part in the third edition of the Riyadh Marathon on February 10 – an increase of more than 33%, with 15,000 runners in 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240211783273/en/
Riyadh Marathon Presented by SAB (Graphic: AETOSWire)
For the first time, the start and finish line, and the accompanying Marathon Village, were located next to Kingdom Arena and Boulevard World. From there, competitors of all ages and abilities could enjoy one of four races – the full marathon (42.2km), half marathon (21.1km), 10km, and 4km family run. Across the four races, there were more than 20,000 participants, with a significant increase in female runners, exceeding 7,200. In total, 64% were males, with 36% female.
The top three elite male marathon runners were Kigen Wilfred Kirwa of Kenya, Tilahun Abe Gashahun of Ethiopia, and El Ghouz Anouar of Morocco, who were awarded US$30,000, US$20,000, and US$10,000 respectively. The top three female elite marathon runners, receiving the same amounts, were Badane Bedatu Hirpa, Desta Nigist Muluneh, and Jebesa Zenebu Fikadu, all from Ethiopia. Prizes for elite runners in the half marathon started at US$5,000 for first place.
SFA President HRH Prince Khaled bin Alwaleed bin Talal Al Saud said: “In line with the mandate of the Saudi Vision 2030 initiative, events such as this are building a healthier, happier population. And with increasing numbers of participants from abroad, we are raising Saudi Arabia’s profile as a sporting nation.”
SFA Managing Director Shaima Saleh Al-Husseini said: “The remarkable figure of 36% female participation underscores our concerted efforts to empower women through sports, and helps to realize the ambitious goals of Saudi Vision 2030. This milestone achievement heralds a brighter, healthier future.”
Organized by the Saudi Sports for All Federation (SFA), in collaboration with the Ministry of Sport, the Saudi Arabian Olympic & Paralympic Committee, and the Saudi Arabian Athletic Federation, the event sponsors included Saudi Awwal Bank, and headline sponsors ROSHN, PepsiCo, ASICS, Twauniya, Genesis, and Al Arabiya, with a total of US$197,000 in cash prizes awarded to winners. The event was also sponsored by JPMorgan, Hisamitsu, Activia, L’Oréal, GSK, CALO, Kudu, Delta Sports, and MDLBeast.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240211783273/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom